Relafen 750, the novel formulation of naproxen, represents a fascinating case from the biochemical pharmacy view. This mode of action, essentially involving inhibition of cyclooxygenase enzymes namely COX-1 and COX-2 – leads to the reduction in prostaglandin creation. From the biochemical framework, the drug's effectiveness is strongly related to